CLARE HOLMES: Open Payments
NPI 1558966614 · LEWES, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$426 in 14 payments from 10 companies in 2025. Trend: 2023 $501 · 2024 $582 · 2025 $426
Food & beverage: $426
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $143 |
| Astellas Pharma US Inc | 2 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| Verona Pharma, Inc. | 2 | $32 |
| Insmed, Inc. | 2 | $32 |
| Merck Sharp & Dohme LLC | 1 | $28 |
| United Therapeutics Corporation | 1 | $26 |
| GENZYME CORPORATION | 1 | $24 |
| ViiV Healthcare Company | 1 | $22 |
| Gilead Sciences, Inc. | 1 | $20 |
Products named: Cresemba, GLASSIA, Ohtuvayre, Arikayce, PIFELTRO, Tyvaso, DUPIXENT, DOVATO.
Industry payments across DE — which companies pay providers there.
